ICAM-1 as a molecular target for triple negative breast cancer

Area of Science:

• Biomedical Engineering
• Oncology
• Nanotechnology

Background:

• Triple-negative breast cancer (TNBC) presents a high mortality rate due to aggressive characteristics and limited treatment options.
• Intercellular adhesion molecule-1 (ICAM-1) is identified as overexpressed in TNBC cell lines and tissues.
• There is a critical need for novel therapeutic targets and diagnostic biomarkers for TNBC.

Purpose of the Study:

• To investigate ICAM-1 as a potential molecular target and biomarker for TNBC.
• To develop and evaluate ICAM-1 antibody-conjugated iron oxide nanoparticles (ICAM-IONPs) as a diagnostic and therapeutic probe for TNBC.
• To assess the in vivo targeting capability and efficacy of ICAM-IONPs in TNBC models.

Main Methods:

• Synthesis of ICAM-1 antibody-conjugated iron oxide nanoparticles (ICAM-IONPs).
• Quantitative analysis of ICAM-1 surface expression on TNBC cells.
• In vivo magnetic resonance imaging (MRI) studies using TNBC xenograft models after systemic administration of ICAM-IONPs.
• Histological and iron quantification analyses of tumor tissues.

Main Results:

• ICAM-1 overexpression was confirmed in human TNBC cell lines and tissues.
• Quantitative ICAM-1 expression correlated with the targeting ability of ICAM-IONPs to TNBC cells.
• Systemic administration of ICAM-IONPs resulted in significant and sustained MRI contrast enhancement in TNBC xenografts.
• Demonstrated probe accumulation in tumors with high ICAM-1 expression, validated by iron quantification and histology.

Conclusions:

• ICAM-1 is a viable molecular target and biomarker for TNBC.
• ICAM-IONPs serve as an effective MRI probe for evaluating TNBC tumor targeting.
• This approach offers a potential new strategy for TNBC diagnosis and therapy, addressing a significant unmet clinical need.